Cantor Fitzgerald initiated coverage of Pharvaris (PHVS) with an Overweight rating and $28 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
- Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
- Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
- Pharvaris Reports 2024 Financial Results and Business Progress
- Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue